The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation

European Journal of Clinical Pharmacology

Volumn 67, Issue 12, 2011, Pages 1231-1241

  De Wildt, Saskia N ^b   Van Schaik, Ron H N ^c   Soldin, Offie P ^d   Soldin, Steve J ^d   Brojeni, Parvaneh Yazdani ^a   Van Der Heiden, Ilse P ^c   Parshuram, Chris ^a   Nulman, Irena ^a,f   Koren, Gideon ^a,e  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d GEORGETOWN UNIVERSITY   (United States)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

ABCB1; CYP3A5; Kidney transplant; Liver transplant; Pediatrics; Pharmacokinetics; Tacrolimus

Indexed keywords

TACROLIMUS;

ABCB1 GENE; ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CHILDHOOD MORTALITY; CONTROLLED STUDY; CYP3A5 GENE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG MONITORING; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GRAFT RECIPIENT; GRAFT REJECTION; HAPLOTYPE; HOMOZYGOSITY; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MARKER GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; P-GLYCOPROTEIN; SEVERITY OF ILLNESS INDEX; TACROLIMUS;

EID: 82455187996     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1083-7     Document Type: Article

References (44)

1. S Masuda K Inui 2006 An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients Pharmacol Ther 112 1 184 198 16759707 10.1016/j.pharmthera.2006.04.006 1:CAS:528: DC%2BD28XptFCitrY%3D (Pubitemid 44301492)
2. CE Staatz SE Tett 2004 Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation Clin Pharmacokinet 43 10 623 653 15244495 10.2165/00003088-200443100-00001 1:CAS:528:DC%2BD2cXmvFansLc%3D (Pubitemid 38981845)
3. M Naesens O Salvatierra L Li N Kambham W Concepcion M Sarwal 2008 Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients Transplantation 85 8 1139 1145 18431234 10.1097/TP.0b013e31816b431a 1:CAS:528:DC%2BD1cXltVGktrk%3D (Pubitemid 351596397)
4. H Zheng S Webber A Zeevi E Schuetz J Zhang P Bowman G Boyle Y Law S Miller J Lamba GJ Burckart 2003 Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms Am J Transplant 3 4 477 483 12694072 10.1034/j.1600-6143.2003.00077.x 1:CAS:528:DC%2BD3sXksVGgu7g%3D (Pubitemid 36560101)
5. S Yu L Wu J Jin S Yan G Jiang H Xie S Zheng 2006 Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation Transplantation 81 1 46 51 16421475 10.1097/01.tp.0000188118.34633.bf 1:CAS:528:DC%2BD28XkvF2qsg%3D%3D (Pubitemid 43122147)
6. L Quteineh C Verstuyft V Furlan A Durrbach A Letierce S Ferlicot AM Taburet B Charpentier L Becquemont 2008 Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients Basic Clin Pharmacol Toxicol 103 6 546 552 19067682 10.1111/j.1742-7843.2008.00327.x 1:CAS:528:DC%2BD1cXhsFSnsbrL
7. IA MacPhee S Fredericks T Tai P Syrris ND Carter A Johnston L Goldberg DW Holt 2004 The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation Am J Transplant 4 6 914 919 15147425 10.1111/j.1600-6143.2004.00435.x 1:CAS:528:DC%2BD2cXls1Sgurc%3D (Pubitemid 38745590)
8. DR Kuypers H de Jonge M Naesens E Lerut K Verbeke Y Vanrenterghem 2007 CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients Clin Pharmacol Ther 82 6 711 725 17495880 10.1038/sj.clpt.6100216 1:CAS:528:DC%2BD2sXht1ymu7vF (Pubitemid 350114816)
9. DA Hesselink RH van Schaik IP van der Heiden M van der Werf PJ Gregoor J Lindemans W Weimar T van Gelder 2003 Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 3 245 254 12966368 10.1016/S0009-9236(03)00168-1 1:CAS:528:DC%2BD3sXmvVKmsbY%3D (Pubitemid 37083100)
10. M Ferraresso A Tirelli L Ghio P Grillo V Martina E Torresani A Edefonti 2007 Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients Pediatr Transplant 11 3 296 300 17430486 10.1111/j.1399-3046.2006.00662.x 1:CAS:528:DC%2BD2sXmtFegsLk%3D (Pubitemid 46570148)
11. JS Chen LS Li DR Cheng SM Ji QQ Sun Z Cheng JQ Wen GZ Sha ZH Liu 2009 Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus Transplant Proc 41 5 1557 1561 19545678 10.1016/j.transproceed.2009.01.097 1:CAS:528:DC%2BD1MXnsV2rtro%3D
12. Quteineh L, Verstuyft C (2010) Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients. Curr Opin Organ Transplant 15 (5): 601-607
13. AF Hawwa PJ McKiernan M Shields JS Millership PS Collier JC McElnay 2009 Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant Br J Clin Pharmacol 68 3 413 421 19740399 10.1111/j.1365-2125.2009.03461.x 1:CAS:528:DC%2BD1MXht1ylsL3K
14. S Satoh H Kagaya M Saito T Inoue M Miura K Inoue K Numakura N Tsuchiya H Tada T Suzuki T Habuchi 2008 Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients Br J Clin Pharmacol 66 2 207 214 18429967 10.1111/j.1365-2125.2008.03188.x 1:CAS:528:DC%2BD1cXhtVegs7rJ (Pubitemid 351991443)
15. CE Haas DC Kaufman CE Jones AH Burstein W Reiss 2003 Cytochrome P450 3A4 activity after surgical stress Crit Care Med 31 5 1338 1346 12771600 10.1097/01.CCM.0000063040.24541.49 1:CAS:528:DC%2BD3sXlvFans7c%3D (Pubitemid 36583841)
16. A Nanashima P Pillay DJ Verran D Painter M Nakasuji M Crawford L Shi AG Ross 2002 Analysis of initial poor graft function after orthotopic liver transplantation: experience of an Australian single liver transplantation center Transplant Proc 34 4 1231 1235 12072325 10.1016/S0041-1345(02)02639-8 1:STN:280:DC%2BD38zjtVWiuw%3D%3D (Pubitemid 34665326)
17. MM Pollack UE Ruttimann PR Getson 1988 Pediatric risk of mortality (PRISM) score Crit Care Med 16 11 1110 1116 3048900 10.1097/00003246-198811000- 00006 1:STN:280:DyaL1M%2FgsVWlsg%3D%3D (Pubitemid 18267293)
18. A Volosov KL Napoli SJ Soldin 2001 Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry Clin Biochem 34 4 285 290 11440728 10.1016/S0009-9120(01) 00235-1 1:CAS:528:DC%2BD3MXlvF2qs7k%3D (Pubitemid 32607570)
19. AJ Aarnoudse JP Dieleman LE Visser PP Arp IP van der Heiden RH van Schaik M Molokhia A Hofman AG Uitterlinden BH Stricker 2008 Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration Pharmacogenet Genomics 18 4 299 305 18334914 10.1097/FPC.0b013e3282f70458 1:CAS:528:DC%2BD1cXjtVKjtbo%3D (Pubitemid 351367523)
20. ER Lepper SD Baker M Permenter N Ries RH van Schaik PW Schenk DK Price D Ahn NF Smith G Cusatis RG Ingersoll SE Bates RH Mathijssen J Verweij WD Figg A Sparreboom 2005 Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients Clin Cancer Res 11 20 7398 7404 16243813 10.1158/1078-0432.CCR-05-0520 1:CAS:528:DC%2BD2MXhtFartbvM (Pubitemid 41507700)
21. ML Becker LE Visser RH van Schaik A Hofman AG Uitterlinden BH Stricker 2009 Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males Pharmacogenomics 10 11 1743 1751 19891551 10.2217/pgs.09.105 1:CAS:528:DC%2BD1MXhtlOiu77E
22. JS Leeder 2001 Pharmacogenetics and pharmacogenomics Pediatr Clin North Am 48 3 765 781 11411304 10.1016/S0031-3955(05)70338-2 1:STN:280: DC%2BD3MzkvVKjtA%3D%3D (Pubitemid 32521715)
23. MJ Blake A Gaedigk RE Pearce LR Bomgaars ML Christensen C Stowe LP James JT Wilson GL Kearns JS Leeder 2007 Ontogeny of dextromethorphan O- and N-demethylation in the first year of life Clin Pharmacol Ther 81 4 510 516 17301735 10.1038/sj.clpt.6100101 1:CAS:528:DC%2BD2sXkvFymu7w%3D (Pubitemid 46452306)
24. W Zhao V Elie G Roussey K Brochard P Niaudet V Leroy C Loirat P Cochat S Cloarec JL Andre F Garaix A Bensman M Fakhoury E Jacqz-Aigrain 2009 Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients Clin Pharmacol Ther 86 6 609 618 19865079 10.1038/clpt.2009.210 1:CAS:528:DC%2BD1MXhsVWmu7jO
25. M Fukudo I Yano S Masuda M Goto M Uesugi T Katsura Y Ogura F Oike Y Takada H Egawa S Uemoto K Inui 2006 Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients Clin Pharmacol Ther 80 4 331 345 17015051 10.1016/j.clpt.2006.06.008 1:CAS:528:DC%2BD28XhtVWqurvF (Pubitemid 44479749)
26. Hawwa AF, McElnay JC (2011) Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant. Expert Opin Drug Saf 10:9-22
27. K Hosohata S Masuda A Yonezawa T Katsura F Oike Y Ogura Y Takada H Egawa S Uemoto K Inui 2009 MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients Pharm Res 26 7 1590 1595 19267185 10.1007/s11095-009-9867-5 1:CAS:528:DC%2BD1MXivVajs7k%3D
28. J Lamba S Strom R Venkataramanan KE Thummel YS Lin W Liu C Cheng V Lamba PB Watkins E Schuetz 2006 MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype Clin Pharmacol Ther 79 4 325 338 16580901 10.1016/j.clpt.2005.11.013 1:CAS:528:DC%2BD28XjtFaiur0%3D
29. V Haufroid M Mourad V Van Kerckhove J Wawrzyniak M De Meyer DC Eddour J Malaise D Lison JP Squifflet P Wallemacq 2004 The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 14 3 147 154 15167702 10.1097/00008571-200403000-00002 1:CAS:528:DC%2BD2cXjt1Kjsrs%3D (Pubitemid 38373108)
30. H Tada N Tsuchiya S Satoh H Kagaya Z Li K Sato M Miura T Suzuki T Kato T Habuchi 2005 Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplant Proc 37 4 1730 1732 15919447 10.1016/j.transproceed.2005.02.073 1:CAS:528: DC%2BD2MXks1Crs78%3D (Pubitemid 40790812)
31. SH Akbas T Bilgen I Keser M Tuncer L Yucetin O Tosun M Gultekin G Luleci 2006 The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients Transplant Proc 38 5 1290 1292 16797284 10.1016/j.transproceed.2006.02.079 1:CAS:528:DC%2BD28XlvFGnurg%3D
32. D Anglicheau C Verstuyft P Laurent-Puig L Becquemont MH Schlageter B Cassinat P Beaune C Legendre E Thervet 2003 Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients J Am Soc Nephrol 14 7 1889 1896 12819250 10.1097/01.ASN.0000073901.94759.36 1:CAS:528:DC%2BD3sXksV2ju7k%3D (Pubitemid 36750485)
33. D Li R Gui J Li Z Huang X Nie 2006 Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms Transplant Proc 38 9 2850 2852 17112846 10.1016/j.transproceed.2006.08.089 1:CAS:528: DC%2BD28Xht1CisrvM (Pubitemid 44737980)
34. JS Kim DH Aviles DM Silverstein PL Leblanc V Matti Vehaskari 2005 Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients Pediatr Transplant 9 2 162 169 15787787 10.1111/j.1399-3046.2005.00263.x 1:CAS:528:DC%2BD2MXjvVGhtb0%3D (Pubitemid 40476842)
35. G Montini F Ujka C Varagnolo L Ghio F Ginevri L Murer BS Thafam C Carasi G Zacchello M Plebani 2006 The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients Pediatr Nephrol 21 5 719 724 16550361 10.1007/s00467-006-0014-9
36. M Yasuhara T Hashida M Toraguchi Y Hashimoto M Kimura K Inui R Hori Y Inomata K Tanaka Y Yamaoka 1995 Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations Transpl proc 27 1 1108 1110 1:STN:280:DyaK2M7osVequw%3D%3D
37. PE Wallemacq V Furlan A Moller A Schafer P Stadler I Firdaous AM Taburet R Reding S Clement De Clety J De Ville De Goyet E Sokal L Lykavieris V Van Leeuw O Bernard JB Otte NA Undre 1998 Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients Eur J Drug Metab Pharmacokinet 23 3 367 370 9842978 10.1007/BF03192295 1:CAS:528:DyaK1cXnvFWmtr8%3D (Pubitemid 28517723)
38. JY Kausman B Patel SD Marks 2008 Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients Pediatr Transplant 12 3 329 335 18435608 10.1111/j.1399-3046.2007.00821.x 1:CAS:528: DC%2BD1cXmtFKrsLc%3D (Pubitemid 351589446)
39. JF Goorhuis R Scheenstra PM Peeters MJ Albers 2006 Buccal vs. nasogastric tube administration of tacrolimus after pediatric liver transplantation Pediatr Transplant 10 1 74 77 16499591 10.1111/j.1399-3046.2005.00402.x
40. H Ekberg RD Mamelok TC Pearson F Vincenti H Tedesco-Silva P Daloze 2009 The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study Transplantation 87 9 1360 1366 19424036 10.1097/TP.0b013e3181a23cb2 1:CAS:528:DC%2BD1MXlsFKru7g%3D
41. Lock JF, Malinowski M, Schwabauer E, Martus P, Pratschke J, Seehofer D, Puhl G, Neuhaus P, Stockmann M (2011) Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post-transplant week. Clin Transplant 25:436-443
42. R Reding E Sokal K Paul M Janssen V Evrard L Wilmotte C Chardot JB Otte P Wallemacq 2002 Efficacy and pharmacokinetics of tacrolimus oral suspension in pediatric liver transplant recipients Pediatr Transplant 6 2 124 126 12000467 10.1034/j.1399-3046.2002.01052.x 1:CAS:528:DC%2BD3sXis1GgtLw%3D (Pubitemid 34493031)
43. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng AE, Subra JF, Beaune P, Legendre C (2010) Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 87:721-726
44. Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y (2010) Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit 32 (4): 394-404